Sorafenib in Liver Function Impaired Advanced Hepatocellular Carcinoma
Status:
Completed
Trial end date:
2016-07-30
Target enrollment:
Participant gender:
Summary
Due to the HBV and HCV infection, about 55% hepatocellular carcinoma patients happened in
China. Among them, only 10% patients can be diagnosed in early stage. Sorafenib increased PFS
and OS in advanced hepatocellular carcinoma patients with liver function of Child-Pugh class
A patients, but the result for Child-Pugh class B patients is unclear.